BRAF and melanoma: Our results suggest that dual targeting of WNT5A and RhoA signaling is a more effective strategy for controlling the invasion of BRAF wild‐type and BRAFV600 mutated melanomas treated with a BRAF inhibitor than targeting either of the proteins individually.